Recently, i3 Health provided a continuing medical education/nursing continuing professional development/continuing pharmacy education (CME/NCPD/CPE)–approved activity, Best Practices in the Management of Tumor Lysis Syndrome Associated With Emerging Cancer Therapies, during which clinicians' knowledge gaps were challenged and knowledge gains were achieved. Tumor lysis syndrome (TLS) is a rare, potentially life-threatening oncologic emergency typically associated with chemotherapy-induced tumor c...

i3 Health has provided an educational activity that has challenged knowledge gaps experienced by clinicians regarding management and novel treatment options for differentiated and anaplastic thyroid cancer. Thyroid cancer is one of the most prevalent cancers in the United States. The American Cancer Society estimates 43,720 new cases and 2,120 deaths from the disease in the United States over the course of 2023. Thyroid cancer is typically more aggressive in men than in women and becomes increas...

i3 Health has provided an educational activity that has challenged knowledge gaps experienced by nursing staff regarding updated treatment options and optimal patient care for immune thrombocytopenia (ITP). ITP is an autoimmune platelet disorder in which the blood does not clot normally as a result of a low platelet count, causing bruising and bleeding. Research has shown that the burden of ITP is significant; in a survey of more than 1,300 patients from 13 different countries, 36% reported a hi...

An educational enduring online activity provided by i3 Health has provided knowledge gains pertaining to enhancing treatment tolerability, adherence, and patient-centered care for metastatic breast cancer. In the United States, breast cancer accounts for approximately 30% of cancer diagnoses among women and is the second-leading cause of cancer death. The American Cancer Society has estimated that in 2022 there will be 287,580 new cases of invasive breast cancer, with 43,250 of these cases resul...

An educational activity provided by i3 Health has produced knowledge gains and expertise regarding the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). In the United States, prostate cancer is the most common tumor type affecting men. The American Cancer Society estimated for 2022 that there will be 268,490 new cases diagnosed, with 34,500 of these cases resulting in death. Most patients with mHSPC present with relapse after local treatment, while approximately 5% of all p...

An educational activity provided by i3 Health has bridged knowledge gaps experienced by nursing professionals and other health care professionals on the topic of treatment strategies for patients with non-Hodgkin lymphoma (NHL). Accounting for 4% of all cancers diagnosed, NHL is one of the most common cancer types in the United States. The American Cancer Society estimated that 80,470 new diagnoses of NHL will occur in 2022, with 20,250 resulting in death. Aggressive subtypes, including diffuse ...

An educational activity provided by i3 Health has addressed knowledge gaps and produced expertise pertaining to treatment strategies for cholangiocarcinoma. Cholangiocarcinoma, also known as bile duct cancer, is a rare malignancy originating in the epithelium of the bile duct. The American Cancer Society estimates that 8,000 cases of bile duct cancer are diagnosed each year, but it is acknowledged that this number could be higher due to the cancer being hard to diagnose and the potential for mis...